Mogelijk gemaakt door Google TranslateTranslate
Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Latest Press Releases
View all
TimeHeadline
6m agoAs U.S. Markets Surge Like the Dot-Com Boom Era, ELEKTROS Inc. Celebrates a Powerful Rise in Global Momentum As Penny Stock and Microcap Investors Worldwide Continue Discovering the Company's Vision for Hard Rock Lithium Mining and EV Patent Technology
YesterdayDelivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
YesterdayRefers to Item 7 on the agenda: Report on the audit of the consolidated financial statements of Grupa Kęty SA
YesterdayThe 4th BOCHK Science and Technology Innovation Prize Award Ceremony Concludes with Great Success
YesterdayBuffalo Potash Files Annual Information Form and New Technical Report
Arch Biopartners, Inc. logo

Arch Biopartners, Inc.

About

0.45CAD+0.00 +0.00%
Closed • Updated at 17:06 GMT+00:00
Market Cap$21.93M
Volume33.9K
Beta1.15
RSI42.89
Health TechnologyPharmaceuticals: Major

Arch Biopartners, Inc. — investor relations, events, news, and company updates on 6ix.

Latest News

Apr 30 2026
Royal Columbian Hospital begins patient recruitment in Arch Biopartners' Phase II trial of LSALT peptide targeting CS-AKI
Mar 24 2026
Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial
Mar 20 2026
Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide
Feb 9 2026
Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
Jan 16 2026
Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

Community Chat

Ask AI

Try asking
6ix6ixAIEvents